Biomm S.A.

São Paulo Stock Exchange BIOM3.SA

Biomm S.A. Return on Equity (ROE) for the year ending December 31, 2023: -66.38%

Biomm S.A. Return on Equity (ROE) is -66.38% for the year ending December 31, 2023, a -14.10% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Biomm S.A. Return on Equity (ROE) for the year ending December 31, 2022 was -58.17%, a 19.12% change year over year.
Biomm S.A. Return on Equity (ROE) for the year ending December 31, 2021 was -71.93%, a -94.62% change year over year.
Biomm S.A. Return on Equity (ROE) for the year ending December 31, 2020 was -36.96%, a -1.68% change year over year.
Biomm S.A. Return on Equity (ROE) for the year ending December 31, 2019 was -36.35%, a 9.40% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

São Paulo Stock Exchange: BIOM3.SA

Biomm S.A.

CEO	Mr. Heraldo Carvalho Marchezini
IPO Date	Jan. 11, 2000
Location	Brazil
Headquarters	Rua dos Pinheiros, 610
Employees	130
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Pet Food

Description

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.

Key trends

Past 5 years